Rapid automated detection of ABL kinase domain mutations in imatinib-resistant patients

Ruriko Tanaka, Shinya Kimura, Eishi Ashihara, Mariko Yoshimura, Naoto Takahashi, Hisashi Wakita, Kuniaki Itoh, Kaichi Nishiwaki, Kenshi Suzuki, Rina Nagao, Hisayuki Yao, Yoshihiro Hayashi, Sakiko Satake, Hideyo Hirai, Ken ichi Sawada, Oliver G. Ottmann, Junia V. Melo, Taira Maekawa

Research output: Contribution to journalArticlepeer-review

12 Citations (Scopus)


ABL tyrosine kinase inhibitor (TKI), imatinib is used for BCR-ABL + leukemias. We developed an automatic method utilizing guanine-quenching probes (QP) to detect 17 kinds of mutations frequently observed in imatinib-resistance. Results were obtained from 100μL of whole blood within 90min by this method. Detected mutations were almost identical between QP method and direct sequencing. Furthermore, the mutation-biased PCR (MBP) was added to the QP method to increase sensitivity, resulting earlier detection of T315I mutation which was insensitive to any ABL TKIs. Thus, the QP and MBP-QP may become useful methods for the management of ABL TKI-treated patients.

Original languageEnglish
Pages (from-to)228-234
Number of pages7
JournalCancer Letters
Issue number2
Publication statusPublished - Dec 22 2011
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research


Dive into the research topics of 'Rapid automated detection of ABL kinase domain mutations in imatinib-resistant patients'. Together they form a unique fingerprint.

Cite this